Cite
APA Citation
Frost, N., Christopoulos, P., Kauffmann-Guerrero, D., Stratmann, J., Riedel, R., Schaefer, M., Alt, J., Gütz, S., Christoph, D. C., Laack, E., Faehling, M., Fischer, R., Fenchel, K., Haen, S., Heukamp, L., Schulz, C., & Griesinger, F. (2021). lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program. Therapeutic advances in medical oncology, 13, . http://access.bl.uk/ark:/81055/vdc_100125807783.0x000006